“AI Regulations on the Brink: Are Lifescience Professionals Facing a Cross-Border Catastrophe?”
In an era where artificial intelligence is edging its way into everyday life, it’s hard not to wonder: how will shifting AI regulations impact the collaboration that drives life sciences forward? A newly released survey by the Pistoia Alliance in collaboration with the CCC (Copyright Clearance Center) uncovers some striking insights. Despite a commendable 83% of life science professionals embracing generative AI to enhance their research, a daunting 85% express worries about how differing regulations could hinder cross-border collaboration. Moreover, a surprising 42% confess to not considering copyright implications when utilizing third-party information with AI tools. As these innovators gathered at this year’s US conference in Philadelphia, the conversation turned to the pressing issues of harmonizing standards, addressing regulatory ambiguities, and ensuring patient-centricity. The urgency is palpable, especially when one in five researchers has yet to harness the potential of AI. With complex challenges ahead, the path to safe AI adoption in research is not just a solo endeavor—it’s a collective journey. Curious about the full findings and what these stats mean for the future of pharma R&D? LEARN MORE
Survey: 85 percent of lifescience professionals concerned about impact of differing AI regulations on cross-border collaboration
Post Comment